The ciRNA™
Platform

Circurna’s ribozyme catalyzes the formation of circular RNA — a molecular architecture designed for stability

Circular RNA designed for durability and real-world application

Circurna’s proprietary ciRNA™ circular RNA platform is designed to address key limitations of first-generation linear mRNA technologies, including short-lived protein expression, tolerability challenges, and reliance on ultra-cold-chain logistics.

By using a circular RNA format, Circurna is developing RNA therapeutics intended to support sustained protein expression, improved tolerability, and formulations suitable for distribution and use outside controlled laboratory settings.

Circurna’s platform is built to support multiple therapeutic modalities within a single, consistent technology framework. Rather than optimizing RNA for a single application, the ciRNA™ platform is designed to scale across programs and disease areas.

Key objectives of the platform include:

Sustained therapeutic protein expression
Improved tolerability relative to linear mRNA approaches
Formulations suitable for room-temperature stability
Flexible delivery options to support patient accessibility

Programs advancing in parallel through a data-driven platform.

Circurna’s pipeline spans oncology, fibrosis, autoimmune, infectious diseases and other chronic conditions, intentionally designed to demonstrate platform versatility while accelerating development through shared data and rapid decision-making.

Platform Pillars:

Durable Expression

The ciRNA™ platform is designed to support sustained protein production in vivo, enabling longer-lasting therapeutic activity and the potential for lower or less frequent dosing.

Improved Tolerability

Optimized RNA design and manufacturing processes that yield high-purity products, reduce innate immune reactogenicity commonly associated with linear mRNA technologies.

Thermostable Formulations

Circurna has developed proprietary lipid nanoparticle formulations designed to remain stable at room temperature, reducing reliance on specialized cold-chain infrastructure and enabling global distribution.

Flexible Delivery

The platform supports multiple administration routes, including injection-free microneedle patches, designed to improve patient accessibility and adherence.

Circurna’s CiRNA™ Therapeutics: Safe, thermostable and needle-free

RNA

Circular RNA is Stable Inside Cells

Immune and Protein Response

Generates strong, sustained immunity and high antibody titers; therapeutics expressed for long period of time.

Rapid Scalability Easily adaptable

For new immunization therapeutics, powered by AI for faster development.

Thermostable Nanoparticles

Stays stable at room temperature, removing the need for cold storage.

Microneedle Patch Delivery

Painless self-administration improves compliance.

Therapeutic
Applications

The ciRNA™ platform is being developed to support a broad range of applications, including:

In situ cellular reprogramming, including in vivo CAR-T approaches and gene editing
Protein therapeutics, including expression of antibodies, peptides, and multi-payload constructs
Immunization therapeutics, modulating host immune and autoimmune responses

These applications span across multiple indications.

Development Strategy

Circurna’s development strategy is designed to achieve speed, rigor, and capital efficiency. Platform-level insights from early programs are intended to inform and accelerate subsequent indications, reducing risk and supporting disciplined expansion. The company’s lead infectious disease program is intended to provide early clinical validation of the ciRNA™ platform, while oncology, fibrosis, and chronic disease programs represent longer-term value drivers.

The ciRNA™ Platform